ClinicalTrials.gg
RecruitingNCT05941910Updated Jul 12, 2023

The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function

A Phase 2 interventional study of Q10 in Non-Alcoholic Fatty Liver Disease, sponsored by Attikon Hospital. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Attikon Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece — 3 open to participants now, 6 under way, 2 of them phase 3. Non-alcoholic Fatty Liver Disease · Greece.

Planned enrollment
15th of 20
60 · median 100
Started
2023
with 2 others
Phase 2
8 of 24
1 open now
Registered
20th of 24
by date
Lead sponsor
1 of 24
Attikon Hospital

Among the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 in phase 2, and was the 20th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

3 of the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, or all of them as a file.
02

Study summary

Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD

Read the detailed description

Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD. In this trial patients with NAFLD will receive 240mg Q10 or placebo. At baseline and at 6 months, will be measured: a) Perfused boundary region (PBR) of the sublingual vessels using the SideviewDarkfieldimaging technique (Microscan, Glycocheck), b) pulse wave velocity (PWV-Complior, ALAM), c) flow-mediated dilation (FMD) of the brachial artery, d) left ventricular (LV) global longitudinal strain (GLS), and e) controlled attenuation parameter (CAP)for the quantification of liver steatosis by liver elastography (Fibroscan, Echosens).

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease

Keywords

  • Non-alcoholic fatty liver disease
  • endothelial function
  • vascular function
  • myocardial function
  • coronary flow reserve
  • endothelial glycocalyx
  • flow mediated dilation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NAFLD AND one of below :

    1. dyslipidemia, as it is defined in the metabolic syndrome
    2. increased waist circumference as defined in the metabolic syndrome
    3. Arterial hypertension,
    4. overweight, (>25)
    5. polycystic ovary syndrome,

Exclusion criteria

Exclusion Criteria:

  • Chronic Kidney Disease
  • Heart Failure
  • Liver failure
  • Pregnancy/ Breast feeding
  • Active (receiving Chemotherapy/immunotherapy)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Q10

    Drug: Q10

  • Placebo comparator
    Placebo

    Drug: Q10

Interventions

06

What researchers measure

Primary outcomes

  1. The effect of Q10 on Left Ventricular Myocardial Function

    The effect of Q10 on Left Ventricular Global Longitudinal Strain after six month administration of Q10

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
  • Vaia Lambadiari
    Athens, Attiki 12462, Greece
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Aug 2023, 4 months after the start.

Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's planned 4 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 12, 2023
StartActual
Apr 1, 2023
Primary completionEst.
Aug 14, 2023
CompletionEst.
Dec 31, 2023
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05941910
Lead sponsor
Attikon Hospital
Responsible party
VAIA LAMBADIARI (Professor of Internal Medicine-Endocrinology, Attikon Hospital) — Principal investigator
First posted
Jul 12, 2023
Start date
Apr 1, 2023
Primary completion
Aug 14, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jul 12, 2023

Study contacts

Vaia Lambadiari, Profesor
Contact
vlambad@otenet.gr
2105831148

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Coenzyme Q10

Start the discussion